Month: January 2021

January 26, 2021AkzoNobel share buyback (January 18, 2021 – January 22, 2021)AkzoNobel (AKZA; AKZOY) has repurchased 216,000 of its own common shares in the period from January 18, 2021, up to and including January 22, 2021, at an average price of €87.12 per share. The consideration of the repurchase was €18.82 million.This is part of a repurchase program announced on October 21, 2020. AkzoNobel intends to repurchase common shares up to a value of €300 million. The total number of shares repurchased under this program to date is 1,275,776 ordinary shares for a total consideration of €112.45 million.The share buyback is due to be completed in the first half of 2021. The company has engaged a third party to manage the program and perform transactions on its behalf. It is intended that the shares will be cancelled following repurchase.The...

Press Release26 January 2021Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma (STS)Immunicum AB (publ; IMMU.ST) announced today that it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the Company’s lead candidate, ilixadencel, a cell-based, off-the-shelf immune primer, for the treatment of Soft Tissue Sarcoma (STS). The designation recognizes results from the Phase I/II clinical trial in Gastrointestinal Stromal Tumors (GIST), a rare and difficult-to treat cancer indication belonging to the group of cancers referred to as Soft Tissue Sarcoma.“We continue to build recognition for ilixadencel’s potential and are pleased to announce that in addition to designations for ilixadencel in Renal Cell Carcinoma and Hepatocellular Carcinoma,...

Pressmeddelande26 januari 2021Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel för behandling av mjukdelssarkom, Soft Tissue Sarcoma (STS)Immunicum AB (publ; IMMU.ST) tillkännager idag att bolaget har erhållit särläkemedelsstatus (Orphan Drug Designation, ODD) från den amerikanska läkemedelsmyndigheten, FDA, för bolagets ledande kandidat ilixadencel, en cellbaserad och lagringsbar immunaktiverare, för behandling av mjukdelssarkom (Soft Tissue Sarcoma, STS). FDA:s beslut grundas bland annat på resultaten från den kliniska fas I/II-studien i gastrointestinal stromacellstumör (GIST), en sällsynt och svårbehandlad cancersjukdom som hör till cancergruppen mjukdelssarkom.“Vi fortsätter att få bekräftelse på ilixadencels potential och är glada över att kunna meddela att förutom ilixadencels tidigare erhållna s.k....

NORDIC ID OYJYHTIÖTIEDOTE 26.1.2021 KELLO 09:00          NORDIC ID Oyj on solminut merkittävän sopimuksen teknologian kehittämisestä ja laitetoimituksistaNordic ID Oyj on solminut monivuotisen myynti- ja tuotekehityssopimuksen pitkäaikaisen kumppaninsa kanssa. Sopimus on monivuotinen ja se sisältää minimiostovelvoitteen kehitettävälle laitteelle. Sopimuksen arvo on vähintään miljoona euroa. Sopimuskumppanin nimeä ei julkisteta sopimuskumppanin pyynnöstä liikesalaisuuden suojelemiseksi.Toimitusjohtaja Juuso Lehmuskoski:”Yhteistyössä kehitettävä ratkaisu tavoittaa uusia asiakaskohderyhmiä ja tarjoaa sekä Nordic ID:lle että kumppanillemme vahvan alustan rakentaa uutta liiketoimintaa RFID teknologian avulla. Nyt solmittu sopimus osoittaa Nordic ID:n kyvyn kehittää uudenlaisia ratkaisuja ja luoda niiden avulla arvokasta liiketoimintaa”Lisätietoja:Juuso...

 Paris, 26 janvier 2021Selon l’article 223-16 du réglement général de l’Autorité des Marchés Financiers,au 26 janvier 2021A PROPOS D’ECOSLOPSEcoslops est cotée sur Euronext Growth à ParisCode ISIN : FR0011490648 – Mnémonique : ALESA / éligible PEA-PME, et FCPIContact Relations investisseurs : info.esa@ecoslops.com – 01 83 64 47 43Ecoslops est la cleantech qui fait entrer le pétrole dans l’économie circulaire grâce à une technologie innovante,permettant de produire du carburant et du bitume léger à partir de résidus pétroliers. La solution proposée par Ecoslopsrepose sur un procédé industriel unique de micro-raffinage de ces résidus pour les transformer enproduits commerciaux aux standards internationaux. Ecoslops offre aux infrastructures portuaires,aux collecteurs de résidus ainsi qu’aux armateurs une solution économique...

Tryg’s Supervisory Board has today approved the annual report 2020.Premium growth of 7.0% (6.1% excluding Alka in 2019). The technical result of DKK 3,495m (DKK 3,237m) was impacted by continued positive developments in the core business, the delivery of the Alka synergies and lower than normal large and weather claims. Investment income of DKK 311m (DKK 579m) driven by positive financial market returns in a year characterized by significant volatility after the outbreak of COVID-19 in the first quarter of 2020 and related worries regarding the macroeconomic environment. Profit before tax of DKK 3,541m (DKK 3,628m). Quarterly dividend of DKK 1.75 per share, supporting TryghedsGruppen’s member bonus. Solvency ratio of 183.  Financial highlights 2020Premium growth of 7.0% (6.1% excluding Alka in 2019) in local currenciesTechnical result...

Trygs bestyrelse har i dag godkendt årsrapporten for 2020. Præmievækst på 7,0 % (6,1 % eksklusive Alka i 2019). Forsikringsteknisk resultat på 3.495 mio. DKK (3.237 mio. DKK) påvirket af fortsat positiv udvikling i kerneforretningen, Alka synergier samt et lavt niveau af stor- og vejrskader. Investeringsresultatet udgjorde 311 mio. DKK (579 mio. DKK) og var positivt påvirket af de finansielle markeder i et år karakteriseret af stor volatilitet efter udbruddet af COVID-19 i første kvartal 2020 samt usikkerhed om den makroøkonomiske udvikling. Resultat før skat udgjorde 3.541 mio. DKK (3.628 mio. DKK). Kvartalsvis udbytte på 1,75 DKK pr. aktie, som bidrager til TryghedsGruppens medlemsbonus. Solvensratio på 183.Finansielle højdepunkter 2020Præmievækst på 7,0 % (6,1 % eksklusive Alka i 2019) i lokal valutaForsikringsteknisk resultat på 3.495...

The Dutch Ministry of Public Works and Waterways has awarded Heijmans a five-year contract for the maintenance of waterways in the central-eastern part of the Netherlands (Oost-Nederland). The performance contract covers the Boven-Rijn and Waal rivers and the Maas-Waal canal and represents a value of around € 32 million for Heijmans.Option to extend by three yearsThe contract became definitive on Monday, 25 January. In addition to the initial term of five years, the contract includes an option to extend the contract for an additional term of three years. From Q3 2021, Heijmans will carry out daily work on the above-mentioned waterways. This will include waterway maintenance (dredging), bank maintenance (breakwaters, longitudinal dams, extended banks, bank walls), the maintenance of pavements and moorings in overnight mooring facilities),...

Heijmans gaat de komende vijf jaar het onderhoud aan de vaarwegen in Oost-Nederland uitvoeren. Het prestatiecontract van Rijkswaterstaat betreft de Boven-Rijn, Waal en het Maas-Waalkanaal. Deze opdracht heeft voor Heijmans een waarde van circa € 32 miljoen.Optie tot 3 jaar verlengingHet Prestatiecontract Oost-Nederland Vaarwegen (perceel 1) is op maandag 25 januari definitief gegund aan Heijmans. Bovenop de contractperiode van 5 jaar ligt een optie tot 3 jaar verlenging. Vanaf Q3 2021 zal Heijmans op dagelijkse basis werkzaamheden verrichten aan de genoemde waterwegen. Dat betreft onder meer het vaargeulonderhoud (baggeren), oeveronderhoud (kribben, langsdammen, gestrekte oevers, damwanden), onderhoud aan verhardingen en aanlegvoorzieningen in overnachtingshavens) en het inspecteren, schouwen, herstellen van schades en verhelpen van storingen.Hoogste...

Press release                                                                                     Ecully, 25 January 2021 – 6 p.m.2020 annual results18% increase in operating incomeImproved performances during the second half of 2020Continued strengthening of the financial structure           · Spineway’s Board of Directors, at a meeting held on 25 January 2021 chaired by Stéphane Le Roux, closed the 2020 annual accounts.Thanks to a sharp increase in sales in December 2020 (+30% compared with December 2019), Spineway’s revenue for Q4 2020 was up 21% compared with Q3, at €1 068K. This positive momentum, buoyed, in particular, by an increase in sales in Asia during the fourth quarter (+71% compared with 2019), allowed the Group’s annual revenue to reach €3 379K, closing the gap a bit with 2019 (-33%) in a year that was greatly disrupted...